share_log

Mangoceuticals | 8-K: Current report

SEC ·  Oct 1 19:35

Summary by Futu AI

On October 1, 2024, Mangoceuticals, Inc., also known as MangoRx, announced the launch of its new oral Semaglutide weight loss treatment named 'Slim.' The product is now available for purchase on the company's telemedicine platform. This launch represents a significant step for MangoRx in addressing the growing global GLP-1 market, which is projected to expand from $49.3 billion in 2024 to $157.5 billion by 2035. 'Slim' is offered as an oral dissolvable tablet compounded with Vitamin B6, providing a convenient alternative to injections. MangoRx's CEO, Jacob Cohen, expressed optimism about the product's potential to meet increasing consumer demand for effective weight management solutions. The company has competitively priced 'Slim' at $299 per month, aiming to make the treatment accessible to a broad customer base. MangoRx focuses on men's health and wellness products and services, including erectile dysfunction, hair growth, hormone replacement therapies, and weight management, all available through its secure telemedicine platform.
On October 1, 2024, Mangoceuticals, Inc., also known as MangoRx, announced the launch of its new oral Semaglutide weight loss treatment named 'Slim.' The product is now available for purchase on the company's telemedicine platform. This launch represents a significant step for MangoRx in addressing the growing global GLP-1 market, which is projected to expand from $49.3 billion in 2024 to $157.5 billion by 2035. 'Slim' is offered as an oral dissolvable tablet compounded with Vitamin B6, providing a convenient alternative to injections. MangoRx's CEO, Jacob Cohen, expressed optimism about the product's potential to meet increasing consumer demand for effective weight management solutions. The company has competitively priced 'Slim' at $299 per month, aiming to make the treatment accessible to a broad customer base. MangoRx focuses on men's health and wellness products and services, including erectile dysfunction, hair growth, hormone replacement therapies, and weight management, all available through its secure telemedicine platform.

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.